Figure 7
Analysis of the binding of mouse sera to cells after the two immunisation schedules: protocol 1 with soluble anti-Id scFv 40 and 69 and protocol 2 with phage-displayed scFv. The binding experiments were performed either on (A) CHO cells which do not express the HER2/neu receptor or (B) SK-OV-3-cells overexpressing HER2/neu receptor. The binding of antibodies was detected by FACS analysis using an FITC-labelled goat anti-mouse antibody. All antibody binding experiments were performed in comparison with trastuzumab detected using a FITC-labelled anti-human antibody and with the background fluorescence determined by binding on cells of the FITC-labelled secondary antibody alone. Curves indicate background fluorescence (solid line), control mAb trastuzumab (
), sera from mice immunised with PBS (
), sera from mice immunised with anti-Id scFv 40 (
), sera from mice immunised with anti-Id scFv 69 (•), and sera from mice immunised with HER-2/neu ECD-Fc (
).
